Physician profile
Mony Fraer
NPI 1497845960
$4,630.17
in general payments reported to CMS, 2019-2025
12 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $600 · 2021: $1,257 · 2022: $893 · 2023: $90.00 · 2024: $916 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,385.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Medical Corporation | $1,295.00 | 2022-2025 | Defibrillator |
| Vertex Pharmaceuticals Incorporated | $729.17 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $610.00 | 2020-2021 | |
| Allergan, INC. | $496.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Vifor (International) LTD. | $300.00 | 2020 | |
| Becton, Dickinson and Company | $270.00 | 2022 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $200.00 | 2022 | |
| Glaxosmithkline, LLC. | $180.00 | 2022-2023 | Benlysta |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mony Fraer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.